{"transactions":[{"id":2443115,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares Warrant (right to buy)","published_at":"2022-01-05T12:43:50.000Z","date":"2021-10-05","kind":"other","acquired":false,"shares":2220000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These reported securities were disposed of pursuant to the Issuer's transaction with Xeris Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc. (\"Holdco\") and Wells MergerSub, Inc., a wholly owned subsidiary of Holdco, pursuant to a Transaction Agreement dated May 24, 2021 (the \"Transaction Agreement) in which Holdco would acquire the Issuer (the \"Acquisition\") by means of a scheme of arrangement (the \"Scheme\") under Irish law for a per share consideration of 0.7840 newly issued shares of Holdco common stock, and cash in lieu of fractions thereof, plus one contingent value right worth up to an additional $1.00 payable in cash, Holdco common stock or a combination thereof at Holdco's sole election. Pursuant to the Transaction Agreement, the Issuer's outstanding warrants were treated as follows: (i) each outstanding and unexercised Strongbridge Private Placement Warrant was assumed by Holdco such that the applicable holders will have the right to subscribe for Holdco Shares,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from Footnote 1) in accordance with certain terms of the Strongbridge Private Placement Warrant, (ii) each outstanding and unexercised Strongbridge Assumed Warrant was assumed by Holdco such that, upon exercise, the applicable holders will have the right to have delivered to them the Reference Property, in accordance with certain terms of the Strongbridge Assumed Warrants (each defined in the Transaction Agreement). Effective as of October 5, 2021, Holdco completed the Acquisition pursuant to the Scheme. The foregoing description of the Transaction Agreement is qualified in its entirety by reference to the Transaction Agreement, which is filed as Exhibit 2.1 to the Form 8-K filed by the Issuer on May 24, 2021, and is incorporated by reference herein."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These reported securities were disposed of pursuant to the Issuer's transaction with Xeris Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc. (\"Holdco\") and Wells MergerSub, Inc., a wholly owned subsidiary of Holdco, pursuant to a Transaction Agreement dated May 24, 2021 (the \"Transaction Agreement) in which Holdco would acquire the Issuer (the \"Acquisition\") by means of a scheme of arrangement (the \"Scheme\") under Irish law for a per share consideration of 0.7840 newly issued shares of Holdco common stock, and cash in lieu of fractions thereof, plus one contingent value right worth up to an additional $1.00 payable in cash, Holdco common stock or a combination thereof at Holdco's sole election. Pursuant to the Transaction Agreement, the Issuer's outstanding warrants were treated as follows: (i) each outstanding and unexercised Strongbridge Private Placement Warrant was assumed by Holdco such that the applicable holders will have the right to subscribe for Holdco Shares,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) in accordance with certain terms of the Strongbridge Private Placement Warrant, (ii) each outstanding and unexercised Strongbridge Assumed Warrant was assumed by Holdco such that, upon exercise, the applicable holders will have the right to have delivered to them the Reference Property, in accordance with certain terms of the Strongbridge Assumed Warrants (each defined in the Transaction Agreement). Effective as of October 5, 2021, Holdco completed the Acquisition pursuant to the Scheme. The foregoing description of the Transaction Agreement is qualified in its entirety by reference to the Transaction Agreement, which is filed as Exhibit 2.1 to the Form 8-K filed by the Issuer on May 24, 2021, and is incorporated by reference herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities represent (a) 2,100,000 Warrants that were owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to have been indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 120,000 Warrants that were beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to have been indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."}],"balance_after":0,"derivative":{"exercise_price":2.5,"exercise_date":"2017-06-28","expiration_date":"2022-06-28","underlying":"Ordinary Shares, $0.01 par value","underlying_shares":2220000},"source":{"system":"sec-edgar","filing":"0000919574-22-000043","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957422000043/ownership.xml","form_type":"4"}},{"id":2443114,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2022-01-05T12:43:50.000Z","date":"2021-10-05","kind":"other","acquired":false,"shares":8060682,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These reported securities were disposed of pursuant to the Issuer's transaction with Xeris Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc. (\"Holdco\") and Wells MergerSub, Inc., a wholly owned subsidiary of Holdco, pursuant to a Transaction Agreement dated May 24, 2021 (the \"Transaction Agreement) in which Holdco would acquire the Issuer (the \"Acquisition\") by means of a scheme of arrangement (the \"Scheme\") under Irish law for a per share consideration of 0.7840 newly issued shares of Holdco common stock, and cash in lieu of fractions thereof, plus one contingent value right worth up to an additional $1.00 payable in cash, Holdco common stock or a combination thereof at Holdco's sole election. Pursuant to the Transaction Agreement, the Issuer's outstanding warrants were treated as follows: (i) each outstanding and unexercised Strongbridge Private Placement Warrant was assumed by Holdco such that the applicable holders will have the right to subscribe for Holdco Shares,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from Footnote 1) in accordance with certain terms of the Strongbridge Private Placement Warrant, (ii) each outstanding and unexercised Strongbridge Assumed Warrant was assumed by Holdco such that, upon exercise, the applicable holders will have the right to have delivered to them the Reference Property, in accordance with certain terms of the Strongbridge Assumed Warrants (each defined in the Transaction Agreement). Effective as of October 5, 2021, Holdco completed the Acquisition pursuant to the Scheme. The foregoing description of the Transaction Agreement is qualified in its entirety by reference to the Transaction Agreement, which is filed as Exhibit 2.1 to the Form 8-K filed by the Issuer on May 24, 2021, and is incorporated by reference herein."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These reported securities were disposed of pursuant to the Issuer's transaction with Xeris Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc. (\"Holdco\") and Wells MergerSub, Inc., a wholly owned subsidiary of Holdco, pursuant to a Transaction Agreement dated May 24, 2021 (the \"Transaction Agreement) in which Holdco would acquire the Issuer (the \"Acquisition\") by means of a scheme of arrangement (the \"Scheme\") under Irish law for a per share consideration of 0.7840 newly issued shares of Holdco common stock, and cash in lieu of fractions thereof, plus one contingent value right worth up to an additional $1.00 payable in cash, Holdco common stock or a combination thereof at Holdco's sole election. Pursuant to the Transaction Agreement, the Issuer's outstanding warrants were treated as follows: (i) each outstanding and unexercised Strongbridge Private Placement Warrant was assumed by Holdco such that the applicable holders will have the right to subscribe for Holdco Shares,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) in accordance with certain terms of the Strongbridge Private Placement Warrant, (ii) each outstanding and unexercised Strongbridge Assumed Warrant was assumed by Holdco such that, upon exercise, the applicable holders will have the right to have delivered to them the Reference Property, in accordance with certain terms of the Strongbridge Assumed Warrants (each defined in the Transaction Agreement). Effective as of October 5, 2021, Holdco completed the Acquisition pursuant to the Scheme. The foregoing description of the Transaction Agreement is qualified in its entirety by reference to the Transaction Agreement, which is filed as Exhibit 2.1 to the Form 8-K filed by the Issuer on May 24, 2021, and is incorporated by reference herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares represent (a) 7,529,834 Ordinary Shares that were owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to have been indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 530,848 Ordinary Shares that were beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to have been indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000919574-22-000043","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957422000043/ownership.xml","form_type":"4"}},{"id":3025821,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2020-09-21T21:48:26.000Z","date":"2020-09-18","kind":"purchase","acquired":true,"shares":6000,"price":2.2,"value":13200.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Following the transactions reported herein, these shares represent (a) 7,529,834 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 530,848 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."}],"balance_after":8060682,"source":{"system":"sec-edgar","filing":"0000919574-20-005947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957420005947/ownership.xml","form_type":"4"}},{"id":3025820,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2020-09-21T21:48:26.000Z","date":"2020-09-17","kind":"purchase","acquired":true,"shares":1473377,"price":2.25,"value":3315098.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.24 to $2.25 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Following the transactions reported herein, these shares represent (a) 7,529,834 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 530,848 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."}],"balance_after":8054682,"source":{"system":"sec-edgar","filing":"0000919574-20-005947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957420005947/ownership.xml","form_type":"4"}},{"id":3359882,"issuer":{"id":85987,"kind":"organization","name":"Molecular Templates, Inc.","symbol":"MTEM"},"owners":[{"id":138628,"kind":"person","name":"Morenstein Scott D","position":1,"cik":"0001576113","reported_name":"Morenstein Scott D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":2,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":3,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":4,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-25T16:24:33.000Z","date":"2019-11-21","kind":"purchase","acquired":true,"shares":468750,"price":8,"value":3750000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (iii) Scott Morenstein, a Managing Director of the investment manager of CDK Associates, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Scott Morenstein serves as a director of the Issuer. Caxton Corporation, Bruce Kovner and CDK Associates, L.L.C. may be considered directors by deputization due to their affiliation with Scott Morenstein. Each Reporting Person disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":2052991,"source":{"system":"sec-edgar","filing":"0000919574-19-007463","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1183765/000091957419007463/ownership.xml","form_type":"4"}},{"id":3716788,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-12-28T17:39:27.000Z","date":"2018-12-27","kind":"purchase","acquired":true,"shares":18200,"price":3.9799,"value":72434.18,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Following the transactions reported herein, these shares represent (a) 6,244,501 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 336,804 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."}],"balance_after":6581305,"source":{"system":"sec-edgar","filing":"0000919574-18-008212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418008212/ownership.xml","form_type":"4"}},{"id":3716787,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-12-28T17:39:27.000Z","date":"2018-12-26","kind":"purchase","acquired":true,"shares":31197,"price":3.9971,"value":124697.5287,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Following the transactions reported herein, these shares represent (a) 6,244,501 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 336,804 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."}],"balance_after":6563105,"source":{"system":"sec-edgar","filing":"0000919574-18-008212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418008212/ownership.xml","form_type":"4"}},{"id":3716810,"issuer":{"id":85987,"kind":"organization","name":"Molecular Templates, Inc.","symbol":"MTEM"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":138628,"kind":"person","name":"Morenstein Scott D","position":2,"cik":"0001576113","reported_name":"Morenstein Scott D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":3,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":4,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-28T17:30:23.000Z","date":"2018-12-26","kind":"purchase","acquired":true,"shares":25000,"price":3.45,"value":86250.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by CDK Associates, L.L.C. and may be deemed to be beneficially owned by (i) Scott Morenstein, a Managing Director of Caxton Alternative Management LP, the investment manager of CDK Associates, L.L.C., (ii) Caxton Corporation, the manager of CDK Associates, LLC and (iii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Scott Morenstein serves as a director of the Issuer. Caxton Corporation, Bruce Kovner and CDK Associates, L.L.C. may be considered directors by deputization due to their affiliation with Scott Morenstein. Each Reporting Person disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":1584241,"source":{"system":"sec-edgar","filing":"0000919574-18-008210","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1183765/000091957418008210/ownership.xml","form_type":"4"}},{"id":3720792,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-12-21T18:16:24.000Z","date":"2018-12-21","kind":"purchase","acquired":true,"shares":90612,"price":3.9508,"value":357989.8896,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.82 to $4.10 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.\n\n Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Following the transactions reported herein, these shares represent (a) 6,196,882 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 335,026 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."}],"balance_after":6531908,"source":{"system":"sec-edgar","filing":"0000919574-18-008127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418008127/ownership.xml","form_type":"4"}},{"id":3720791,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-12-21T18:16:24.000Z","date":"2018-12-20","kind":"purchase","acquired":true,"shares":146467,"price":3.9967,"value":585384.6589,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.85 to $4.22 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Following the transactions reported herein, these shares represent (a) 6,196,882 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 335,026 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."}],"balance_after":6441296,"source":{"system":"sec-edgar","filing":"0000919574-18-008127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418008127/ownership.xml","form_type":"4"}},{"id":3806486,"issuer":{"id":85987,"kind":"organization","name":"Molecular Templates, Inc.","symbol":"MTEM"},"owners":[{"id":138628,"kind":"person","name":"Morenstein Scott D","position":1,"cik":"0001576113","reported_name":"Morenstein Scott D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":2,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":3,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":4,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-27T15:11:06.000Z","date":"2018-09-25","kind":"purchase","acquired":true,"shares":545454,"price":5.5,"value":2999997.0,"ownership":{"direct":false,"nature":"By CDK Associates, L.L.C."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by CDK Associates, L.L.C. and may be deemed to be beneficially owned by (i) Scott Morenstein, a Managing Director of Caxton Alternative Management LP, the investment manager of CDK Associates, L.L.C., (ii) Caxton Corporation, the manager of CDK Associates, LLC and (iii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Scott Morenstein serves as a director of the Issuer. Caxton Corporation, Bruce Kovner and CDK Associates, L.L.C. may be considered directors by deputization due to their affiliation with Scott Morenstein. Each Reporting Person disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by CDK Associates, L.L.C. and may be deemed to be beneficially owned by (i) Scott Morenstein, a Managing Director of Caxton Alternative Management LP, the investment manager of CDK Associates, L.L.C., (ii) Caxton Corporation, the manager of CDK Associates, LLC and (iii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Scott Morenstein serves as a director of the Issuer. Caxton Corporation, Bruce Kovner and CDK Associates, L.L.C. may be considered directors by deputization due to their affiliation with Scott Morenstein. Each Reporting Person disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":1559241,"source":{"system":"sec-edgar","filing":"0000899243-18-025415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1183765/000089924318025415/doc4.xml","form_type":"4"}},{"id":3848296,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-08-09T12:28:34.000Z","date":"2018-08-08","kind":"purchase","acquired":true,"shares":360995,"price":4.9267,"value":1778514.0665,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.878 to $5.00 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares represent (a) 5,968,147 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 326,682 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and entities affiliated with such employees and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation.\n\n Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":6294829,"source":{"system":"sec-edgar","filing":"0000919574-18-005198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418005198/ownership.xml","form_type":"4"}},{"id":3856624,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-08-01T16:56:23.000Z","date":"2018-07-30","kind":"purchase","acquired":true,"shares":70000,"price":4.6638,"value":326466.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares represent (a) 5,619,678 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 314,156 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and entities affiliated with such employees and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation.\n\n Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":5933834,"source":{"system":"sec-edgar","filing":"0000919574-18-005044","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418005044/ownership.xml","form_type":"4"}},{"id":3859839,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-07-27T18:15:49.000Z","date":"2018-07-27","kind":"purchase","acquired":true,"shares":92400,"price":4.85,"value":448140.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares represent (a) 5,549,678 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 314,156 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and entities affiliated with such employees and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":5863384,"source":{"system":"sec-edgar","filing":"0000919574-18-004961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418004961/ownership.xml","form_type":"4"}},{"id":3859838,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-07-27T18:15:49.000Z","date":"2018-07-27","kind":"purchase","acquired":true,"shares":116900,"price":4.6283,"value":541048.27,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares represent (a) 5,549,678 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 314,156 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and entities affiliated with such employees and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":5771434,"source":{"system":"sec-edgar","filing":"0000919574-18-004961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418004961/ownership.xml","form_type":"4"}},{"id":3859837,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-07-27T18:15:49.000Z","date":"2018-07-26","kind":"purchase","acquired":true,"shares":39800,"price":4.9429,"value":196727.42,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares represent (a) 5,549,678 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 314,156 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and entities affiliated with such employees and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":5654534,"source":{"system":"sec-edgar","filing":"0000919574-18-004961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418004961/ownership.xml","form_type":"4"}},{"id":3859836,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-07-27T18:15:49.000Z","date":"2018-07-24","kind":"purchase","acquired":true,"shares":150000,"price":4.9151,"value":737265.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares represent (a) 5,549,678 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 314,156 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and entities affiliated with such employees and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":5614734,"source":{"system":"sec-edgar","filing":"0000919574-18-004961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418004961/ownership.xml","form_type":"4"}},{"id":3862611,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-07-23T17:33:07.000Z","date":"2018-07-23","kind":"purchase","acquired":true,"shares":20400,"price":4.95,"value":100980.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares represent (a) 5,169,133 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 295,601 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":5464734,"source":{"system":"sec-edgar","filing":"0000919574-18-004871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418004871/ownership.xml","form_type":"4"}},{"id":3862610,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-07-23T17:33:07.000Z","date":"2018-07-20","kind":"purchase","acquired":true,"shares":21100,"price":4.9666,"value":104795.26,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares represent (a) 5,169,133 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 295,601 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":5444334,"source":{"system":"sec-edgar","filing":"0000919574-18-004871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418004871/ownership.xml","form_type":"4"}},{"id":3862609,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-07-23T17:33:07.000Z","date":"2018-07-19","kind":"purchase","acquired":true,"shares":14000,"price":4.9819,"value":69746.6,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares represent (a) 5,169,133 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 295,601 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":5423234,"source":{"system":"sec-edgar","filing":"0000919574-18-004871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418004871/ownership.xml","form_type":"4"}},{"id":3865083,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, $0.01 par value","published_at":"2018-07-18T13:55:31.000Z","date":"2018-07-16","kind":"purchase","acquired":true,"shares":11200,"price":4.9669,"value":55629.28,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares represent (a) 5,113,633 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 295,601 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 3 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":5409234,"source":{"system":"sec-edgar","filing":"0000919574-18-004815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325713/000091957418004815/ownership.xml","form_type":"4"}},{"id":4253264,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2017-07-21T21:54:22.000Z","date":"2017-07-20","kind":"exercise","acquired":false,"shares":2858086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series C Preferred Stock was converted to Common Stock on a 5.2083 for one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Persons are amending the Form 4 originally filed to report the conversion of Series C Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series C Preferred Stock was convertible to Common Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series C Preferred Stock was convertible to Common Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares represent (a) 2,834,466 shares of Series C Convertible Preferred Stock that were owned directly by CDK Associates, LLC, which is a Reporting Person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 23,620 shares of Series C Convertible Preferred Stock that were held in an account of an employee of Caxton Corporation or an affiliate and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"(Continued from Footnote 7) Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":548755},"source":{"system":"sec-edgar","filing":"0000919574-17-005551","document":"p7573916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000091957417005551/p7573916.xml","form_type":"4/A","original_submission_date":"2017-07-20"}},{"id":4253263,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-21T21:54:22.000Z","date":"2017-07-20","kind":"purchase","acquired":true,"shares":215000,"price":15,"value":3225000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares beneficially owned following the acquisition by CDK Associates, LLC of 215,000 shares of Common Stock represent (a) 759,220 shares of Common Stock that are owned directly by CDK Associates, LLC, which is a Reporting Person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 4,535 shares of Common Stock that are held in an account of an employee of Caxton Corporation or an affiliate and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"(Continued from Footnote 4) Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":763755,"source":{"system":"sec-edgar","filing":"0000919574-17-005551","document":"p7573916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000091957417005551/p7573916.xml","form_type":"4/A","original_submission_date":"2017-07-20"}},{"id":4253262,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-21T21:54:22.000Z","date":"2017-07-20","kind":"exercise","acquired":true,"shares":548755,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Persons are amending the Form 4 originally filed to report the conversion of Series C Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series C Preferred Stock was converted to Common Stock on a 5.2083 for one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares represent (a) 544,220 shares of Common Stock that are owned directly by CDK Associates, LLC, which is a Reporting Person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 4,535 shares of Common Stock that are held in an account of an employee of Caxton Corporation or an affiliate and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":548755,"source":{"system":"sec-edgar","filing":"0000919574-17-005551","document":"p7573916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000091957417005551/p7573916.xml","form_type":"4/A","original_submission_date":"2017-07-20"}},{"id":4253252,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2017-07-21T19:58:17.000Z","date":"2017-07-20","kind":"exercise","acquired":false,"shares":2858086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series C Preferred Stock was converted to Common Stock on a 5.2083 for one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Persons are amending the Form 4 originally filed to report the conversion of Series C Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series C Preferred Stock was convertible to Common Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series C Preferred Stock was convertible to Common Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares represent (a) 2,834,466 shares of Series C Convertible Preferred Stock that were owned directly by CDK Associates, LLC, which is a Reporting Person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 23,620 shares of Series C Convertible Preferred Stock that were held in an account of an employee of Caxton Corporation or an affiliate and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"(Continued from Footnote 7) Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":548755},"source":{"system":"sec-edgar","filing":"0000919574-17-005547","document":"p7573916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000091957417005547/p7573916.xml","form_type":"4/A","original_submission_date":"2017-07-20"}},{"id":4253251,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-21T19:58:17.000Z","date":"2017-07-20","kind":"purchase","acquired":true,"shares":215000,"price":15,"value":3225000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares beneficially owned following the acquisition by CDK Associates, LLC of 215,000 shares of Common Stock represent (a) 759,220 shares of Common Stock that are owned directly by CDK Associates, LLC, which is a Reporting Person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 4,535 shares of Common Stock that are held in an account of an employee of Caxton Corporation or an affiliate and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"(Continued from Footnote 4) Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":763755,"source":{"system":"sec-edgar","filing":"0000919574-17-005547","document":"p7573916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000091957417005547/p7573916.xml","form_type":"4/A","original_submission_date":"2017-07-20"}},{"id":4253250,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-21T19:58:17.000Z","date":"2017-07-20","kind":"exercise","acquired":true,"shares":548755,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Persons are amending the Form 4 originally filed to report the conversion of Series C Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series C Preferred Stock was converted to Common Stock on a 5.2083 for one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares represent (a) 544,220 shares of Common Stock that are owned directly by CDK Associates, LLC, which is a Reporting Person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 4,535 shares of Common Stock that are held in an account of an employee of Caxton Corporation or an affiliate and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation.  Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":548755,"source":{"system":"sec-edgar","filing":"0000919574-17-005547","document":"p7573916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000091957417005547/p7573916.xml","form_type":"4/A","original_submission_date":"2017-07-20"}},{"id":4253891,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":131609,"kind":"organization","name":"CDK ASSOCIATES, L.L.C.","position":1,"cik":"0001576081","reported_name":"CDK ASSOCIATES, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118015,"kind":"organization","name":"CAXTON CORP","position":2,"cik":"0001388551","reported_name":"CAXTON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131610,"kind":"person","name":"Kovner Bruce","position":3,"cik":"0001325713","reported_name":"Kovner Bruce","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-20T22:07:01.000Z","date":"2017-07-20","kind":"purchase","acquired":true,"shares":215000,"price":15,"value":3225000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":215000,"source":{"system":"sec-edgar","filing":"0000919574-17-005533","document":"p7572818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000091957417005533/p7572818.xml","form_type":"4"}}]}